BioAtla, Inc. (BCAB)
NASDAQ: BCAB · Real-Time Price · USD
0.3799
+0.0053 (1.41%)
Aug 7, 2025, 4:00 PM - Market closed
1.41%
Market Cap22.19M
Revenue (ttm)11.00M
Net Income (ttm)-61.88M
Shares Out 58.42M
EPS (ttm)-1.21
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume334,170
Open0.3680
Previous Close0.3746
Day's Range0.3680 - 0.3884
52-Week Range0.2400 - 2.5250
Beta0.89
AnalystsBuy
Price Target1.00 (+163.23%)
Earnings DateAug 7, 2025

About ALTR

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company’s lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Dec 16, 2020
Employees 61
Stock Exchange NASDAQ
Ticker Symbol BCAB
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

Analyst Summary

According to 2 analysts, the average rating for BCAB stock is "Buy." The 12-month stock price target is $1.0, which is an increase of 163.23% from the latest price.

Price Target
$1.0
(163.23% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozurifta...

13 hours ago - GlobeNewsWire

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

3 days ago - GlobeNewsWire

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active...

21 days ago - GlobeNewsWire

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients D...

5 weeks ago - GlobeNewsWire

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen

45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; stan...

2 months ago - GlobeNewsWire

BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Offi...

3 months ago - Seeking Alpha

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera...

3 months ago - GlobeNewsWire

BioAtla to Participate in the Citizens Life Sciences Conference

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

3 months ago - GlobeNewsWire

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

3 months ago - GlobeNewsWire

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

3 months ago - GlobeNewsWire

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

3 months ago - GlobeNewsWire

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive O...

4 months ago - Seeking Alpha

BioAtla Cuts 30% of Jobs in Restructuring Effort

The San Diego biopharmaceutical company, which focuses on treating solid tumor cancers, said Thursday its workforce reduction is part of an effort to extend its runway beyond key clinical readouts in ...

4 months ago - Market Watch

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

4 months ago - GlobeNewsWire

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

5 months ago - GlobeNewsWire

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the...

5 months ago - GlobeNewsWire

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "AXL Inhibitors - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights...

5 months ago - GlobeNewsWire

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active...

8 months ago - GlobeNewsWire

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with ...

8 months ago - GlobeNewsWire

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

8 months ago - GlobeNewsWire

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive...

9 months ago - Seeking Alpha

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

BioAtla's proprietary CAB platform offers precise cancer targeting, minimizing harm to healthy cells, with promising clinical trial outcomes for its ADCs and immuno-oncology treatments. The company fa...

10 months ago - Seeking Alpha

BioAtla: Numerous Catalysts Coming In Q4

BioAtla, Inc. has promising pipeline projects, including masked antibodies and ADCs targeting AXL and ROR2, showing early efficacy and potential for improved cancer treatments. Financially, BioAtla fa...

10 months ago - Seeking Alpha

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

10 months ago - GlobeNewsWire

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther...

11 months ago - GlobeNewsWire